Unknown

Dataset Information

0

Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.

ABSTRACT: We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-dependent reductions in food intake and body weight.

SUBMITTER: Sebhat IK 

PROVIDER: S-EPMC4018145 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-dependent reductions in food intake and body weight. ...[more]

Similar Datasets

Unknown Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.
| S-EPMC4025675 | biostudies-literature
Unknown Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of Asthma.
| S-EPMC6047040 | biostudies-literature
Unknown Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients.
| S-EPMC5137193 | biostudies-other
Unknown Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes.
| S-EPMC5949837 | biostudies-other
Unknown Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.
| S-EPMC2593135 | biostudies-literature
Unknown Bombesin receptor subtype 3 as a potential target for obesity and diabetes.
| S-EPMC5417335 | biostudies-literature
Unknown Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality.
| S-EPMC4017983 | biostudies-literature
Unknown Discovery of a potent nicotinic Acid receptor agonist for the treatment of dyslipidemia.
| S-EPMC4017979 | biostudies-literature
Unknown Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.
| S-EPMC4007836 | biostudies-other
Unknown Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.
| S-EPMC4027753 | biostudies-literature